LifeVantage: Costs Keep Falling With Sales — Too Early To Call A Bottom

LifeVantage reported its fiscal fourth quarter after the close on August 27 with revenue down 23.1% to $42.4 million, and still closed the quarter with a profit. Diluted earnings per share were $0.10. That contradiction is the operating-expense story in miniature: in a quarter where sales fell by $12.7 million, total operating expenses fell by $10.5 million, a decline of about 25%. The company is cutting its cost base faster than its business is shrinking.

The line doing the heavy lifting is easy to skim past. Commissions and incentives, the money LifeVantage pays its independent consultants, came to $17.5 million in the quarter, or 41.3% of revenue, versus 42.1% a year earlier. Selling, general and administrative costs were $13.9 million, 32.7% of revenue versus 33.9%. Combined, operating expenses consumed 74.0% of revenue, slightly less than the 76.0% a year ago, and gross margin held at 78.0%. Operating income stayed positive at $1.7 million, and adjusted EBITDA was $2.7 million versus $4.8 million in the year-ago quarter.

Read the commission line twice, because it carries the tell. In a direct-selling business, the commission bill is not a cost you can clamp shut to save money; it is the recruiting and retention machine that produces the sales. Commissions fell mostly because there are fewer people left to pay. Active accounts at June 30 were 104,000, down 21.2% from a year earlier, active independent consultants were 43,000, down 15.7%, and active customers were 61,000, down 24.7%. The expense report and the revenue report are the same story written twice: a shrinking field force writes fewer orders, which trims commissions, and management adds genuine cost restraint on top. That is real discipline, but it is discipline applied to the one engine the company needs to grow rather than idle.

How a business that grew 14% a year earlier got here is the cautionary second half. The engine of fiscal 2025 was the MindBody GLP-1 System, launched in October 2024; full-year revenue rose 14.2% to $228.5 million, with the Americas up 21.5%. When those results were reported, management guided fiscal 2026 revenue to $225 million to $240 million. Instead the weight-management market turned competitive, and the product that had carried growth began to fall against its own strong prior-year quarters: revenue was down 27.8% to $48.9 million in the December quarter, down 25.2% to $43.7 million in the March quarter, and down 23.1% in June. In February management cut its full-year forecast to $185 million to $200 million of revenue. The actual year came in at $182.6 million, below even the low end, with adjusted EBITDA of $13.7 million and adjusted EPS of $0.56 also landing under the reduced ranges. The margin damage shows in the gross line: the company recorded a $2.5 million inventory-obsolescence allowance on the GLP-1 System over the year, and gross margin slipped to 77.6% from 80.4%.

The decision actually sits on the cheap-multiple question. At about $6.45 a share, with roughly 12.5 million shares outstanding and no debt, LifeVantage has a market value near $80 million; after $14.9 million of cash, enterprise value is roughly $66 million. Trailing adjusted EPS of $0.56 puts the stock at about 11.5x, or about 16x GAAP earnings of $0.40; trailing adjusted EBITDA of $13.7 million puts EV/EBITDA near 5x; the dividend yields roughly 3.1%. What is cheap here is a business in active decline, not a healthy franchise that investors temporarily dislike. The stock's 52-week range is $3.90 to $14.28, so the market has already repriced expectations hard. And that is the tension: if fiscal 2027 revenue falls another 15% to 20% toward roughly $150 million and adjusted EBITDA roughly halves, a 5x multiple still implies a meaningfully lower share price. Cheap can get cheaper before a floor is proven.

The support beneath the stock is real but second-order. LifeVantage holds no debt, had $14.9 million of cash at year-end, and generated $10.2 million of operating cash flow in fiscal 2026. The roughly 3% dividend, $0.05 a quarter, costs about $2.5 million a year, which is affordable, and the board raised it 11% back in March and declared it again in August. There is also $58.5 million left on a $60 million buyback authorization, a big number against an $80 million market value — but the company actually repurchased only about $2.0 million of stock during fiscal 2026. Cash flow, not the authorization, sets the pace.

Two things keep this from being a buy-the-fear opportunity yet. First, LifeVantage issued no fiscal 2027 guidance, citing the recent CEO transition. Terrence Moorehead, the new chief executive who started August 5, arrives with the profile the market wants — he previously ran Nature's Sunshine Products, an industry peer, through a multi-year turnaround — but his plan and his numbers do not exist yet, and there is nothing to test. Second, the operating evidence of a bottom simply is not in the quarter: revenue is still falling sequentially (December $48.9 million, March $43.7 million, June $42.4 million), the account base is still contracting by roughly a fifth a year, and adjusted EPS of $0.11 missed the roughly $0.13 consensus, a miss of about 15%.

The investor takeaway is a waiting position, not a rating manufactured to fill space. LifeVantage's Q4 expense report is evidence of a well-defended decline, not of a recovery: the model's biggest cost shrinks automatically because it is tied to the shrinking sales force, and the balance sheet can honor the dividend and fund a trickle of buybacks while revenue falls. That caps the downside. What it does not do is prove a floor, and the absence of guidance means the cheap multiple is a bet on stabilization the numbers have not delivered. The evidence that would change the view is observable within two quarters: a Q1 fiscal-2027 report, expected in early November, showing revenue flattening and active customers stopping their slide, plus the new CEO's first explicit guidance. Until one of those appears, this is a gap between a cheap company and a cheap stock.